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study
Abstract
Background Internationally, there is concern about the increased prescribing of pharmaceutical opioids for
chronic non-cancer pain (CNCP). In part, this is related to limited knowledge about the long-term benefits
and outcomes of opioid use for CNCP. There has also been increased injection of some pharmaceutical
opioids by people who inject drugs, and for some patients, the development of problematic and/or dependent
use. To date, much of the research on the use of pharmaceutical opioids among people with CNCP, have been
clinical trials that have excluded patients with complex needs, and have been of limited duration (i.e. fewer
than 12 weeks). The Pain and Opioids In Treatment (POINT) study is unique study that aims to: 1) examine
patterns of opioid use in a cohort of patients prescribed opioids for CNCP; 2) examine demographic and
clinical predictors of adverse events, including opioid abuse or dependence, medication diversion, other drug
use, and overdose; and 3) identify factors predicting poor pain relief and other outcomes. Methods/Design
The POINT cohort comprises around 1,500 people across Australia prescribed pharmaceutical opioids for
CNCP. Participants will be followed-up at four time points over a two year period. POINT will collect
information on demographics, physical and medication use history, pain, mental health, drug and alcohol use,
non-adherence, medication diversion, sleep, and quality of life. Data linkage will provide information on
medications and services from Medicare (Australia's national health care scheme). Data on those who receive
opioid substitution therapy, and on mortality, will be linked. Discussion This study will rigorously examine
prescription opioid use among CNCP patients, and examine its relationship to important health outcomes.
The extent to which opioids for chronic pain is associated with pain reduction, quality of life, mental and
physical health, aberrant medication behavior and substance use disorders will be extensively examined.
Improved understanding of the longer-term outcomes of chronic opioid therapy will direct community-based
interventions and health policy in Australia and internationally. The results of this study will assist clinicians to
better identify those patients who are at risk of adverse outcomes and who therefore require alternative
treatment strategies.
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Abstract
Background: Internationally, there is concern about the increased prescribing of pharmaceutical opioids for chronic
non-cancer pain (CNCP). In part, this is related to limited knowledge about the long-term benefits and outcomes of
opioid use for CNCP. There has also been increased injection of some pharmaceutical opioids by people who inject
drugs, and for some patients, the development of problematic and/or dependent use. To date, much of the
research on the use of pharmaceutical opioids among people with CNCP, have been clinical trials that have
excluded patients with complex needs, and have been of limited duration (i.e. fewer than 12 weeks). The Pain and
Opioids In Treatment (POINT) study is unique study that aims to: 1) examine patterns of opioid use in a cohort of
patients prescribed opioids for CNCP; 2) examine demographic and clinical predictors of adverse events, including
opioid abuse or dependence, medication diversion, other drug use, and overdose; and 3) identify factors predicting
poor pain relief and other outcomes.
Methods/Design: The POINT cohort comprises around 1,500 people across Australia prescribed pharmaceutical
opioids for CNCP. Participants will be followed-up at four time points over a two year period. POINT will collect
information on demographics, physical and medication use history, pain, mental health, drug and alcohol use,
non-adherence, medication diversion, sleep, and quality of life. Data linkage will provide information on medications
and services from Medicare (Australia’s national health care scheme). Data on those who receive opioid substitution
therapy, and on mortality, will be linked.
Discussion: This study will rigorously examine prescription opioid use among CNCP patients, and examine its
relationship to important health outcomes. The extent to which opioids for chronic pain is associated with pain
reduction, quality of life, mental and physical health, aberrant medication behavior and substance use disorders will
be extensively examined. Improved understanding of the longer-term outcomes of chronic opioid therapy will
direct community-based interventions and health policy in Australia and internationally. The results of this study will
assist clinicians to better identify those patients who are at risk of adverse outcomes and who therefore require
alternative treatment strategies.
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Background
Chronic non-cancer pain (CNCP) is a worldwide, com-
mon complaint. The prevalence of chronic pain (defined
as pain present daily for three months or more) in the
Australian population is 17% for males and 20% for females
[1]. In one survey of 16 European countries, between
10% and 30% of participants reported chronic pain, 16%
of whom said that some days the pain made them “want
to die” [2]. Chronic pain can have a major impact on an
individual and the community, with social, financial,
employment and health costs [2].
CNCP is caused by many factors, including trauma.
The varied aetiology probably impacts upon the effect-
iveness of treatment [1,3-5]. Physical and psychological
factors such as depression and anxiety, a history of psy-
chological trauma, and sleep problems moderate the pain
experience [3]. Context is also important: relationships,
occupational setting and culture all affect the experience
and expression of pain [3]. Between 30-50% of those with
chronic pain in the above study reported that their pain
was not “adequately controlled” [2].
Effective behavioural treatments and non-opioid phar-
macotherapy exist for CNCP [3], but even when a com-
bination of interventions is used, some patients continue
to suffer. The increase in the use of opioid analgesics for
CNCP would suggest that there is conclusive evidence re-
garding their positive impact on pain reduction and qual-
ity of life. Indeed, qualitative and quantitative reviews of
the evidence have concluded that chronic opioid therapy
does produce clinically significant reductions in pain, al-
beit in the range of 2 to 3 points on a 0 to 10 visual
analogue scale, or around 30% [6-8]. Nevertheless, re-
viewers have cautioned that patients need to be carefully
selected and monitored, given that opioids are also associ-
ated with potentially serious harms and significant treat-
ment drop out due to adverse effects [6,7]. Further, the
degree to which pain reduction is achieved varies, and evi-
dence on changes to quality of life and functional status is
inconclusive [6]. Some of this variability in pain reduction
may be related to the type of opioid used, with one meta-
analysis finding that strong but not weak opioids reduced
pain more effectively than other analgesics [9].
Controlled trials have evaluated pharmaceutical opioids
in the treatment of a range of CNCP conditions and have
demonstrated modest attenuation of pain [10]. Evidence
indicates a modest short-term benefit; no studies have yet
run for long enough to demonstrate long-term benefit of
opioids for chronic non-cancer pain. The three systematic
reviews of opioids for chronic non-cancer pain published
to date provide evidence for a modest, short-term anal-
gesic benefit [9,11,12]. This is a best-case scenario because
RCTs select the sub-set of patients most likely to receive a
clinical benefit and have short follow-up periods (average
trial duration of five weeks), meaning they do not report
on longer term outcomes [13,14]. An ongoing systematic
review shows that the only evidence of long-term anal-
gesic benefit (improved physical function and quality of
life) is weak, because it is based on non-blinded studies
with significant potential for reporting bias [6].
There is support from peak pain organisations of the
use of opioids in the treatment of CNCP [2,15-17]. Debate
continues about how, when, and in what manner opioids
should be prescribed for this diverse patient group
[3,18-22]. Consensus statements have recommended
that prescription of opioids for chronic pain is considered
only after following: a thorough assessment of the patient’s
pain problem and history; development of a treatment
plan; consultation with a pain specialist, if necessary; and
regular reviews of patient progress [2,15].
Over the past decade, there has been increasing profes-
sional and public concern in a number of countries about
pharmaceutical opioid use and related harms [23,24]. This
has been driven by increases in prescribing of these drugs,
especially in the USA and Canada. The increase in pre-
scribing in Australia has been less than in Europe and
the United States (US) [25-28], but nonetheless, be-
tween 1992–2007 the number of opioid prescriptions in
Australia increased by around 300% [23]. This increase
in prescribing has been accompanied by increased injec-
tion of some opioids by people who inject drugs [29]; in-
creased concern about the appropriateness of prescribing
these drugs for chronic non-cancer pain (CNCP) [6]; and
for some patients, the development of problematic and/or
dependent use.
The use of opioids, within, and outside the bounds of a
doctor’s prescription has been cause for concern because
of the risk of iatrogenic dependence [30], and opioid over-
doses, with pharmaceutical opioids now comprising the
majority of fatal and non-fatal drug overdoses in the US
[24,31]. A review of 67 studies found that 11.5% of chronic
pain patients engaged in aberrant drug-related behaviours
such as diversion, prescription forgery, injecting, multiple
episodes of prescription loss, escalating doses, and doctor
shopping, 3.3% developed opioid abuse/dependence [32].
Despite this increasing concern, little is known about
the magnitude of risk of such adverse events in patients
prescribed opioids. Clinical trials, because they often ex-
clude more complex patients, including those with comor-
bid conditions that may increase risks for developing
opioid related problems (e.g. history of substance use
disorder), typically find far lower rates of aberrant drug-
related behaviours and abuse/dependence [32]. Many
studies have also been of limited duration (~12 weeks)
and few have examined aberrant drug use behaviours.
Those of longer duration have had a small number of
participants and therefore lack statistical power. Other
studies have examined treatment of localised condi-
tions, e.g. low back pain, or have evaluated a single drug
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or formulation of a drug. Only a few of the studies
reviewed were prospective or longitudinal, thus limiting
the conclusions that can be drawn. Further, there is lit-
tle consensus regarding the diagnosis of opioid depend-
ence in the context of chronic opioid treatment for
chronic pain [33].
Little is known about the patterns of opioid prescrib-
ing for individual patients, and the long term outcomes
for these patients. Small retrospective cohort studies
conducted elsewhere have examined treatment duration,
side effects, pain reduction, and adverse events [34] and
aberrant behaviours [35]. Larger retrospective cohort stud-
ies have examined the risk of overdose [36], the impact on
disability [37], non-medical use [38], conditions treated in
older adults [39], and rates of adverse events [40].
The Pain and Opioid IN Treatment (POINT) study is
an Australian-first study that aims to document patterns
of pharmaceutical opioid prescribing, and risk of adverse
events, in a prospective cohort of patients prescribed
opioids for chronic non-cancer pain.
Methods/Design
Study aims
1. To examine patterns and outcomes of opioid
analgesic use in a cohort of patients prescribed
opioids for chronic non-cancer pain (CNCP).
2. To examine the demographic and clinical predictors
of adverse events among a cohort of CNCP patients,
including opioid abuse or dependence, medication
diversion, other drug use, and overdose.
3. To identify factors which predict poor self-reported
pain relief and other clinical outcomes.
Study design and setting
The POINT study is a prospective cohort study of 1,500
persons who have been prescribed opioids for chronic
non-cancer pain that follows their progress over two
years and examine the predictors of clinical outcomes
over this period. Participants provided consent to link
data on health service utilisation and mortality data; the
study will utilise data linkage to examine other clinical out-
comes in the longer-term, such as opioid substitution ther-
apy utilisation and hospital admissions. Prospective cohort
studies can provide highly reliable and detailed data about
a range of outcomes with the advantage of collecting data
at the time or close to the time an event occurs, reducing
the effects of recall bias [41] and making it easier to draw
causal inferences about associations with later outcomes.
Ethics
The study was approved by the Human Research Ethics
Committee of the University of New South Wales (HREC
reference: # HC12149). The study also received A1
National Pharmacy Guild Approval to approach pharma-
cists to assist with recruitment of participants (Approval
n. 815). Approval was obtained by the Strategic Informa-
tion Design and Governance Branch of the Department of
Human Services to access Medicare data of participants
that consent to access of their records (reference number:
2012/C011091).
Sample size calculations
Power analyses were conducted to estimate minimum
sample size required to assess the potential effects of opi-
oid use on key clinical outcomes. We examine, dropout
due to adverse events as an indicative example.
Power analyses were conducted using GLIMMPSE
[42] to determine the minimum sample size to examine
the potential effect of opioid use on key outcomes. As a
conservative indicative example, we consider changes in
pain score. Data on Australian prescriptions suggests
that approximately 10% of opioid analgesic scripts can
be defined as high dose [43]; we therefore assumed that
at least 10% of the POINT cohort will be on a high dose
of opioid analgesics. The variability of changes in pain
score from baseline over a six month period was esti-
mated from a recent Cochrane review [6]. Even with a
drop-out rate as high as 25%, with an initial sample of
1500 we will be able to detect differences between low
and high dose groups over time as small in magnitude
as 0.30 at above 80% power and a Type I error rate of
5%. These calculations consider the effect of repeated
observations over time (base correlation of 0.5 between
adjacent repeated measures, with a linear exponential
autoregressive decay rate of 0.05) and controlling for a
normally distributed baseline covariate explaining up to
20% of the variation in pain scores. Given that other
research questions relate to more equally balanced sub-
groups (e.g. comparisons of chronic neck/back pain vs.
other types of pain which are distributed in a ratio of
4:1) or outcomes with less variability (e.g. changes in
quality of life: [42]) then we can be confident that the
POINT cohort is sufficiently powered to address the
primary outcomes.
Eligibility criteria
POINT participants were: 18 years or older; competent
in English; and mentally and physically able to complete
telephone and self-complete interviews; without memory
or comprehension difficulties; living with chronic non-
cancer pain (defined as pain present daily for a period of
three months or more); prescribed a Schedule 8 opioid
(an Australian classification of drugs of dependence that
are subject to additional regulatory controls regarding
their manufacture, supply, distribution, possession and use
[44]); and had taken such opioids for CNCP for more than
6 weeks.
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A history of injecting drug use (IDU) was not an ex-
clusion criterion, but those currently prescribed pharma-
ceutical opioids for opioid substitution therapy (OST)
for heroin dependence were not eligible. Nor were those
taking opioids for cancer pain.
Recruitment
A database of pharmacies and chemists across Australia
and their contact details was purchased in May 2012
[45]. The list included 7,136 pharmacies. After removing
duplicates, those that had closed down, or were not suit-
able for the study (i.e. located in a hospital or were a
compounding pharmacy), we had a final list of 5,994
pharmacies.
Each fortnight, approximately, 100–150 pharmacies
were randomly allocated into a Wave (with the exception
of Tasmania which was sampled first). A flyer inviting to
participate in research was faxed to all pharmacies in
the Wave that had a fax number. Any pharmacies who
expressed a lack of interest were not contacted further.
Those who indicated they were interested in more in-
formation, or who did not respond to the fax, were
called and the study was explained to a pharmacist who
was asked if they were willing to participate.
Interested pharmacists were enrolled in the study for a
6-week period because it was expected that most people
on prescription opioids would renew their script within
this time. Pharmacists were asked to approach any cus-
tomers that were prescribed a Schedule 8 opioid for
CNCP for a period of greater than 6 weeks. We were
confident that pharmacists were able to identify cus-
tomers who had CNCP, rather than chronic cancer pain,
by examining the customer’s record for other prescribed
medications. Pharmacists were also able to use the
medication history to confirm that customers had been
on a prescription opioid for more than 6 weeks.
Customers who fit the above criteria were given a flyer
about the study by the pharmacist. Interested customers
were asked whether they would like the pharmacists to
send their details to researchers, or if they wanted to
contact researchers themselves. All flyers had a unique
pharmacy number and pharmacists were reimbursed
$20 for each eligible participant they referred into the
study. POINT staff made reminder calls every fortnight
for the 6 week period to pharmacists.
POINT staff determined the eligibility of those who
were referred to the study, or who contacted the POINT
team. Eligible participants went through a voluntary in-
formed consent process. Those who were willing to par-
ticipate, after being given details of the study, were booked
in for their initial interview which was conducted over
the phone and took approximately 1–1.5 hours. De-
tailed locator information was collected at Baseline to
prevent sample attrition and this was updated at all
follow-up assessments.
Interview procedure
This study had four assessment waves: Baseline, T2 follow
up (3 months), T3 follow up (12 months), and T4 follow
up (24 months) (see Table 1).
Phone interviews were conducted by trained inter-
viewers at the baseline and 24-month time-point. Inter-
viewers had suicide assistance training, a minimum 3-year
health or psychology degree, and were provided glossaries
of general and chronic pain medications and conditions
(see Additional files 1, 2 and 3). A self-completion survey
was sent to all participants at each time-point. Participants
were able to nominate to complete the self-complete sur-
vey either, online, by pen and paper, or on the telephone
with a POINT team member. Participants were reim-
bursed $40 for the baseline interview, $25 at each 3-
month and the 12-month time point and $60 at the
final time point.
Cohort maintenance strategies
There were a number of methods used to prevent attri-
tion in the current study. Firstly, interested participants
(pharmacists or participants) were called within a week
from their expression of interest in the study. Secondly,
participants were offered a variety of study completion
methods, i.e. telephone, pen and paper and online. In
addition to this, we offered to record verbal consent to
participants who found it difficult to return the consent
forms via mail. A variety of methods of study completion
that are flexible and accommodating have been found to
increase retention [46]. Thirdly, a detailed locator form
was completed at the initial contact with participants.
This form gathered detailed information on contact
details of the participants, as well as the contact details
of two secondary contacts (i.e. family, friends, medical
professionals etc.). Finally, participants and pharmacists
were reimbursed within a timely manner for their time
and contribution to the research. Other methods to im-
prove retention were letters thanking the participant for
Table 1 Time-points and data collection method of the POINT prospective cohort
Baseline T2 3 months T3 12 months T4 24 months
• Phone interview • Self-complete questionnaire
(paper and pencil and online
versions)
• Self-complete questionnaire
(paper and pencil and online
versions)
• Phone interview
• Self-complete questionnaire
(paper and pencil and online
versions)
• Self-complete questionnaire
(paper and pencil and online
versions)
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Table 2 Measures, tools, domains and time-points for data collection for the POINT study
Domain Measure Baseline T1 T2 T3 Those who
discontinue
opioids
Demographics
Age and sex ✓ ✕ ✕ ✕ ✕
Marital status, employment, income ✓ ✓ ✓ ✓ ✓
Educational attainment ✓ ✕ ✕ ✕ ✓
Pain
Pain Brief pain Inventory (BPI) [49] ✓ ✓ ✓ ✓ ✓
Current chronic pain diagnosis, incident pain ✓ ✓ ✓ ✓ ✕
Illness and disability history Chronic Conditions section of the CIDI
3.0 [50,51]
✓ ✓ ✓ ✓ ✕
Current physical disabilities 6-items from the Washington Group [52] ✓ ✓ ✓ ✓ ✓
Physical functioning
Physical functioning Brief Pain Inventory (BPI) [51], Short-Form
(SF)-12 [53]
✓ ✓ ✓ ✓ ✓
Exercise Exercise routine and how pain effects this ✓ ✓ ✓ ✓ ✓
Falls Un-standardised questions examining falls ✓ ✕ ✓ ✓ ✓
Sleep Medical Outcome Sleep scale (MOS) [54] ✓ ✓ ✓ ✓ ✓
Coping and pain Pain: Self-Efficacy Questionnaire (PSEQ) [55,56] ✓ ✓ ✓ ✓ ✓
Treatment
Past week use of prescription and OTC
medications and dose
Self-complete 7 day medication diary ✓ ✓ ✓ ✓ ✓
Current prescribed medications and days of use
in last month
✓ ✓ ✓ ✓ ✓
Other treatments for chronic pain ✓ ✓ ✓ ✓ ✓
Perceived effect of treatment Patients’ Global Impression of Change scale
(PGIC) [57]
✓ ✓ ✓ ✓ ✕
Beliefs about medicines Beliefs about Medicines Questionnaires [58] ✓ ✕ ✓ ✓ ✓
Convenience of accessing medications ✓ ✕ ✕ ✕ ✕
Side-effects of opioid medication Pain Assessment and Documentation Tool
(PADT) [59]
✓ ✓ ✓ ✓ ✕
Barriers to treatment ✓ ✓ ✓ ✓ ✓
Reasons for discontinuance of opioids ✕ ✕ ✕ ✕ ✓
Aberrant opioid medication-related behaviours Opioid Related Behaviours In Treatment ORBIT
scale [60]
✓ ✓ ✓ ✓ ✕
Opioid Difficulties Prescribed Opioid Difficulties Scale (PODS) [61] ✓ ✕ ✓ ✓ ✓
Quality of life WHO-QoL-BRIEF [62] ✓ ✓ ✓ ✓ ✓
Mental health
Mental health history ✓ ✕ ✕ ✕ ✕
Depression Patient Health Questionnaire −9 (PHQ-9) [63,64] ✓ ✓ ✓ ✓ ✓
General Anxiety disorder Patient Health Questionnaire (GAD) [65] ✓ ✓ ✓ ✓ ✓
Social Anxiety Social Interaction Anxiety Scale (SIAS) [66] ✓ ✓ ✓ ✓ ✓
Social Phobia Social Phobia Scale (SPS) [66] ✓ ✓ ✓ ✓ ✓
Agoraphobia From the MINI International Neuropsychiatric
Interview [67]
✓ ✓ ✓ ✓ ✓
Post-Traumatic Stress Disorder PC-PTSD [68] ✓ ✓ ✓ ✓ ✓
Borderline personality disorder screener Screener from the CIDI 3.0 [50] ✓ ✕ ✕ ✕ ✕
Child abuse Childhood Trauma Questionnaire [69] ✓ ✕ ✕ ✕ ✕
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involvement in the study; this was sent after a payment
had been made. A newsletter was sent annually to par-
ticipants to provide study updates and progress.
Project governance
A reference group was established for the study which in-
cluded general practitioners, consumers, pain specialists,
addiction medicine specialists, pharmacists and re-
searchers. This reference group was consulted at the be-
ginning of the study to assist in study and questionnaire
design. They were also consulted throughout the study.
Measures
Table 2 shows the measures, tools, domains and time-
points at which data are collected. These measures were
based on recommendations made under the auspices of
the Initiative on Methods, Measurement, and Pain As-
sessment in Clinical Trials (IMMPACT). This Initiative
involved 27 specialists from academia, governmental
agencies, and the pharmaceutical industry who partici-
pated in a consensus meeting and identified core out-
come domains and measures that should be considered
in clinical trials of treatments for chronic pain [47,48].
The draft content of our interview was also reviewed
and discussed by the POINT advisory committee.
Data linkage
Consent was also obtained from POINT participants to
link their data with the following datasets:
Medicare
Medicare (the Australian national health care scheme) col-
lects data on all patient services with medical practitioners
in Australia. The following data fields are collected: item
number; Medicare benefit; date of service, processing or re-
ferral; indication of whether or not the service was provided
in hospital; number of services, rendered or referred; and
State of patient.
National Death Index (NDI)
The NDI is a fully identified database held by the Australian
Institute of Health and Welfare (AIHW) and contains mor-
tality data collected from each of the State and Territory
Births, Deaths and Marriage Registers. It collects informa-
tion on deaths and includes date, state, and causes (primary
causes for all records, secondary causes for deaths in 1997
and later).
Opioid substitution treatment
The Pharmaceutical Drugs of Addiction System (PHDAS)
database is a comprehensive record of all individuals in
NSW who received addictive drugs dispensed by clinicians
with the authorisation of the NSW Director-General of
Health since 1985. The PHDAS is a fully identified
database of all methadone and buprenorphine recipients
(i.e. first name, last name, date of birth, sex, postcode of
residence). As proof of identity must be shown to the pre-
scribing doctor, the name and date of birth variables are of
high quality in this dataset. The database also records pa-
tient admissions and exits from the treatment program,
and the type of pharmacotherapy dispensed.
The data linkage with PHDAS will be performed by prob-
abilistic record linkage software by staff at Medicare (PBS
and Medicare data), AIHW (NDI data) and NSW Health
(PHDAS, NSW hospital data). Variables used for matching
purposes will include: full name, date of birth, sex, date and
state of last known contact where available. Matching will
be performed in several stages (“passes”), commencing with
the strictest of criteria (e.g.: an exact match of full name and
date of birth) to more relaxed criteria (e.g.: slight spelling
and date variations permitted). The records matched in each
pass will be weighted according to the quality of the match.
Data analysis
Descriptive statistics will be used to determine the quan-
tity and type of opioid and other medication use, and the
prevalence of other key variables such as psychiatric disor-
ders, demographics and physical health problems. A range
of standard statistical techniques will be used depending
upon the research question, such as logistic and linear
regressions and survival analysis. Latent class analysis
may be used to examine whether there are differing
latent classes of CNCP participants, and whether such
classes predict clinical outcomes. Generalised estimat-
ing equations (GEE), (statistical techniques for analysing
correlated data) will be used to examine whether the
Table 2 Measures, tools, domains and time-points for data collection for the POINT study (Continued)
Suicidality and self-harm National Survey of Mental Health and
Well-Being
✓ ✕ ✓ ✓ ✓
Social support (SPQ), MOS Social Support [70] ✓ ✓ ✓ ✓ ✓
Locus of control Multidimensional Health Locus of Control
(B, C) [71]
✓ ✕ ✓ ✓ ✓
Substance use
Lifetime and current drug use, illicit drug market ✓ ✓ ✓ ✓ ✓
Drug and alcohol abuse and dependence CIDI 3.0 [50] ✓ ✕ ✕ ✕ ✓
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quantity and type of opioid analgesic use predicts later
health outcomes. Latent growth curve modeling (LGCM)
within a structural equation modeling framework will
examine whether the quantity and type of opioid use
predicts outcomes such as pain relief, quality of life,
functional status, side effects, and psychiatric disorders.
All GEE and LGCM analyses will control for a range of
confounding factors.
Discussion
This project is the first large-scale Australian cohort
study that will rigorously examine opioid analgesic use
among chronic pain patients, and examine the relation-
ship of opioid use to important health outcomes including
mortality. This study will be the first to comprehensively
examine the extent to which opioid therapy for chronic
pain is associated with pain reduction, changed quality of
life, mental and physical health outcomes, aberrant medi-
cation behavior and substance use disorders.
The study will shed light on the extent to which patients
experience problematic opioid use, some of the precursors
and protective factors to problematic use, and the conse-
quences of problematic opioid use related to chronic opi-
oid therapy. It will lead to improved knowledge of dose
changes over time, and the positive and negative outcomes
associated with changes in patterns of opioid use over
time.
Improved understanding of the longer-term outcomes
of chronic opioid therapy will direct community-based
interventions and health policy in Australia. Regulators
across jurisdictions currently use different criteria for
authorising long-term opioid therapy, and different cri-
teria for identifying at-risk patients. The results of this
study will assist doctors and regulators in Australia to
better identify those patients who are at risk of adverse
outcomes and who therefore require alternative treat-
ment strategies.
Finally, the project will achieve the establishment of a
cohort of Australians with chronic pain. The project will
provide the groundwork for further follow-up of the
sample to determine the longer-term outcomes for
chronic pain patients.
Additional files
Additional file 1: Glossary of conditions that may lead to chronic pain.
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